Table 1.

Cutting edge topics of the current controversy on BPA

Are the studies used for regulatory purposes flawed?

Do oral low doses below 5 mg/kg bw/day cause adverse health effects in laboratory animals?

How can differences between industry sponsored and publicly sponsored studies be explained?

Swallow or inject? What is the relevance of the oral route versus implantation of pumps or intravenous injection?

Can rodents be used to extrapolate to the human situation?

To which degree are embryos, babies, or children more susceptible?

How critical is exposure by intravenous infusion in intensive care units?

How critical is tissue deconjugation of BPA-glucuronide and BPA-sulfate?

How can biomonitoring support risk evaluation?

What are the mechanisms of action of BPA? Does the multitude of mechanisms other than estrogen receptor activation make the substance more dangerous?

Why are recent governmental responses inconsistent?